AJHE2305 - CME/CMLE - Progression of Hodgkin lymphoma and plasma cell neoplasms Report from the 2021 SH/EAHP Workshop-Progression of Hodgkin lymphoma and plasma cell neoplasms Report from the 2021 SH/EAHP Workshop

Progression of Hodgkin lymphoma and plasma cell neoplasms Report from the 2021 SH/EAHP Workshop

Pdf Summary

The review article summarizes cases from the 2021 Society for Hematopathology/European Association for Haematopathology Workshop on the progression of Hodgkin lymphoma (HL) and plasma cell neoplasms. It focuses on clinical, morphologic, and molecular findings in cases progressing from HL and plasma cell neoplasms, highlighting dysregulation of cell-signaling pathways like NF-κB and JAK/STAT in HL pathogenesis and genetic complexity in plasma cell neoplasms. Various cases of HL progression to different lymphomas are discussed to emphasize the importance of understanding molecular mechanisms for prognostic and therapeutic improvements. Molecular testing in plasma cell neoplasms revealed mutations like KRAS, with a focus on transformations to conditions like plasma cell leukemia and genetic alterations associated with poor prognosis. The document discusses genetic and epigenetic changes in Hodgkin lymphoma and plasma cell myeloma, underlining the significance of understanding these for better prognosis and potential therapeutic strategies. Additionally, it mentions cases of secondary B-lymphoblastic leukemia linked to therapy for PCM, stressing the importance of genetic profiling for risk stratification and targeted therapies. The study aims to enhance understanding of the pathogenesis and transformation mechanisms of these neoplasms for improved treatment outcomes.

Keywords

Hodgkin lymphoma progression

plasma cell neoplasms

NF-κB pathway

JAK/STAT pathway

genetic complexity

molecular testing

KRAS mutations

prognostic improvements

therapeutic strategies

genetic profiling